Mark L. Powell
Agilent Technologies (United States) · 39 works · 2,277 citations · h-index 16
Top works
- Bioanalytical Method Validation—A Revisit with a Decade of Progress
- Direct-injection LC–MS–MS method for high-throughput simultaneous quantitation of simvastatin and simvastatin acid in human plasma
- A strategy for a post‐method‐validation use of incurred biological samples for establishing the acceptability of a liquid chromatography/tandem mass‐spectrometric method for quantitation of drugs in biological samples
- A versatile system of high-flow high performance liquid chromatography with tandem mass spectrometry for rapid direct-injection analysis of plasma samples for quantitation of a β-lactam drug candidate and its open-ring biotransformation product
- Comparative Bioavailability and Pharmacokinetics of Three Formulations of Albuterol
- Ternary-column system for high-throughput direct-injection bioanalysis by liquid chromatography/tandem mass spectrometry
- Direct injection versus liquid-liquid extraction for plasma sample analysis by high performance liquid chromatography with tandem mass spectrometry
- Quantitative analysis of albuterol in human plasma by combined gas chromatography chemical ionization mass spectrometry
- Relative merits of two methods of sample introduction in inductively coupled plasma mass spectrometry: electrothermal vaporisation and direct sample insertion
- Absolute configuration of glycerol derivatives. 7. Enantiomers of 2-[[[2-(2,6-dimethoxyphenoxy)ethyl]amino]ethyl]-1,4-benzodioxane (WB-4101), a potent competitive .alpha.-adrenergic antagonist
- An automated method for the determination of a new potential antiepileptic agent (CGP 33101) in human plasma using high performance liquid chromatography
- Absolute configuration of glycerol derivatives. 6. Cupra A circular dichroism spectra of 3-(aryloxy)-1-(alkylamino)-2-propanol. .beta.-Adrenergic blocking agents
- PHARMACOKINETICS OF A NEW ANTICONVULSANT(CGP 33101) IN EPILEPTIC MALE PATIENTS AND HEALTHY MALE SUBJECTS AFTER SINGLE ASCENDING ORAL DOSES OF 400–1200 mg
- An automated method of sample preparation of biofluids using pierceable caps to eliminate the uncapping of the sample tubes during sample transfer
- Multiple‐Dose Albuterol Kinetics
- Acute and subchronic toxicity of a nonsulfhydryl angiotensin-converting enzyme inhibitor
- Increased throughput in quantitative bioanalysis using parallel‐column liquid chromatography with mass spectrometric detection
- Comparative steady state bioavailability of conventional and controlled‐release formulations of albuterol
- EVIDENCE FOR AN ARENE OXIDE-NIH SHIFT PATHWAY IN THE METABOLIC CONVERSION OF PROPRANOLOL TO 4’-HYDROXYPROPRANOLOL IN THE RAT AND IN MAN
- Derivatives of .beta.-adrenergic antagonists: N-nitrosopropranolol and N-hydroxypropranolol and its aldonitrone